While mTORC1-selective inhibitors, or rapalogs, have shown some promise in targeting CLL through their ability to induce cell cycle arrest by modulating the mTOR/S6K pathway [19–21], a deeper understanding of the molecular processes that are deregulated in B cell malignancies downstream of mTOR is required to identify novel and potentially more selective therapeutic avenues. The gene discussed is MTOR; the disease is B-cell chronic lymphocytic leukemia.